Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4506-4513

  Barnes, George L ^a   Hebert, Kerri E ^a   Kamal, Mohammad ^a   Javed, Amjad ^b   Einhorn, Thomas A ^a   Lian, Jane B ^b   Stein, Gary S ^b   Gerstenfeld, Louis C ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX2;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE ACTIVITY; GENE DISRUPTION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OSSIFICATION; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL;

ADENOCARCINOMA; ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYTOKINES; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM PROTEINS; OSTEOCLASTS; OSTEOGENESIS; STROMAL CELLS; TRANSCRIPTION FACTORS;

EID: 3042825286     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3851     Document Type: Article

References (52)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
2. Mundy GR. Mechanisms of bone metastasis. Cancer (Phila) 1997;80:1572-80.
3. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: review of methods. Potential and implications. Scanning Electron Microsc 1986;IV:1537-54.
4. Diel IJ, Slomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
5. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335: 1785-91.
6. Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002;62:5571-79.
7. Bendre MS, Montague DC, Peery T, et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003;33:28-37.
8. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001;100:18-24.
9. Sotiriou C, Lacroix M, Lespagnard L, et al. Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 2001;169:87-95.
10. Suarez-Cuervo C, Harris KW, Kallman L, Vaananen HK, Selander KS. Tumor necrosis factor-alpha induces interleukin-6 production via extracellular- regulated kinase 1 activation in breast cancer. Breast Cancer Res Treat 2003;80:71-8.
11. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8.
12. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267:632-7.
13. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002;198:228-36.
14. Kakonen S-M, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (Phila) 2002;97:834-9.
15. Bellahcene A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996;11:665-70.
16. Waltregny D, Bellahcene A, de Leval X, et al. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000;15:834-43.
17. Barnes GL, Javed A, Kamal MH, et al. Osteoblast related transcription factors Runx2 (Cbfal/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003;63:2631-7.
18. Selvamurugen N, Partridge NC. Constitutive expression and regulation of collagenase-3 in human breast cancer cells. Mol Cell Biol Res Commun 2000;3:218-23.
19. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003; 278:48684-9.
20. Komori T, Kishimoto T. Cbfa1 in bone development. Curr Opin Genet Dev 1998;8: 494-9.
21. Lian JB, Stein GS. Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Des 2003;9:2677-85.
22. Ducy P, Zhang R, Geoffrey V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:677-80.
23. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-64.
24. Banerjee C, McCabe LR, Choi JY, et al. Runt homology domain proteins in osteoblast differentiation: AML3/Cbfa1 is a major component of a bone specific complex. J Cell Biochem 1997;66:1-8.
25. Pratap J, Galindo M, Zaidi SK, et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 2003;63:5357-62.
26. Thirunavukkarasu K, Miles RR, Halladay DL, et al. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotogerin, a potent inhibitor of osteoclast differentiation and function. J Biol Chem 2000;275:25163-72.
27. Gao YH, Shinki T, Yuasa T, et al. Potential role of Cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem Biophys Res Commun 1998;252:697-702.
28. Enomoto H, Shiojiri S, Hoshi K, et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotogerin regulation and partial rescue of osteoclastogenesis in Runx2-/-mice by RANKL transgene. J Biol Chem 2003;278:23971-7.
29. Zelzer E, Glotzer DJ, Hartmann C, et al. Tissue specific regulation of VEGF expression during bone development requires Cbfal/Runx2. Mech Dev 2001;106: 97-106.
30. Porte D, Tuckerman J, Becker M, et al. Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 1999;18:667-78.
31. Jimenez MJ, Balbin M, Lopez JM, et al. Collagenase 3 is a target of Cbfal, a transcription factor of the runt gene family involved in bone formation. Mol Cell Biol 1999;19:4431-42.
32. Harada H, Tagashira S, Fujiwara M, et al. Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem 1999;274:6972-8.
33. Javed A, Barnes GL, Jasanya BO, et al. Runt homology domain transcription factors (Runx, Cbfa, and AML) mediate repression of the bone sialoprotein promoter: evidence for promoter context-dependent activity of Cbfa proteins. Mol Cell Biol 2001;21:2891-905.
34. Stein GS, Lian JB, Stein JL, et al. Intranuclear organization of Runx transcriptional regulatory machinery in biological control of skeletogenesis and cancer. Blood Cells Mol Dis 2003;30:170-6.
35. Aronson BD, Fisher AL, Blechman K, Caudy M, Gergen JP. Groucho-dependent and independent repression activities of Runt domain proteins. Mol Cell Biol 1997;17: 5581-7.
36. Hanai J, Chen LF, Kanno T, et al. Interaction and functional cooperation of PEBP2/CBF with smads. Synergistic induction of the immunoglobulin germline ca promoter. J Biol Chem 1999;274:31577-82.
37. Javed A, Guo B, Hiebert S, et al. Groucho/TLE/R-Esp proteins associate with the nuclear matrix and repress Runx dependent activation of tissue-specific gene transcription. J Cell Sci 2000;113:2221-31.
38. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing Yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18:2551-62.
39. Zhang YW, Yasui N, Kakazu N, et al. A Runx2/PEBP2alphaA/Cbfa1 mutation displaying impaired transactivation and smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA 2000;97:10549-54.
40. Gutierrez S, Javed A, Tennant DK, et al. CCAAT/enhancer-binding proteins (C/EBP) β and δ activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem 2002;277: 1316-23.
41. Stein GS, Lian JB, Stein JL, et al. Temporal and spatial parameters of skeletal gene expression: targeting Runx factors and their co-regulatory proteins to subnuclear domains. Connect Tissue Res 2003;44:149-53.
42. Lian JB, Stein JL, Stein GS, et al. Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res 2003;44:141-8.
43. Barseguian K, Lutterbach B, Hiebert SW, et al. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins. Proc Natl Acad Sci USA 2002;99:15434-9.
44. Downing JR. The aml-1-eto chimeric transcription factor in acute myeloid leukemia: biology and clinical significance. Br J of Haematol 1999;106:296-308.
45. Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999;13: 1025-36.
46. Ueta C, Iwamoto M, Kanatani N, et al. Skeletal malformations caused by over expression of Cbfa1 or its dominant negative form in chondrocytes. J Cell Biol 2001;153:87-99.
47. Iwamoto M, Kitagaki J, Tamamura Y, et al. Runx2 expression and action in chondrocytes are regulated by retinoid signaling and parathyroid hormone-related peptide (PTHrp). Osteoarthritis Cartilage 2003;11:6-15.
48. Sun L, Vitolo M, Passaniti A. Runt-related gene 2 in endothelial cells: inducible expression and specific regulation of cell migration and invasion. Cancer Res 2001; 61:4994-5001.
49. Lee Y, Schwarz E, Davies M, et al. Differences in cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003;21:62-72.
50. Kuznetsov SA, Kresbach PM, Satomura K, et al. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997;12:1335-47.
51. Gerstenfeld LC, Cho TJ, Kon T, et al. Impaired fracture healing in the absence of TNF-a signaling: the role of TNF-a in endochondral cartilage resorption. J Bone Miner Res 2003;18:1584-92.
52. Atkins GJ, Kostakis P, Pan B, et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003;18:1088-98.